Supplier News: Siegfried, Lonza, WuXi STA, BD & More
By

The latest from CDMOs, CMOs, and suppliers featuring Siegfried, Lonza, WuXi STA, F.I.S., Pace Life Sciences, Bora Pharmaceuticals, and BD.

Chemicals/Chemical API Manufacturing
* Siegfried Breaks Ground on $104-M Drug-Substance Mfg Plant
* Lonza Completes HPAPI Mfg Expansion
* F.I.S. Creates Two Commercial Divisions, Appoints Executives to Lead
Biologics Manufacturing
* Lonza Name New Head of Cell & Gene Division
Formulation Development/Drug Product Manufacturing
* WuXi STA Opens Sterile Lipid Nanoparticle Mfg Facility
* Pace Life Sciences Acquires Biopharma Global
* Bora Pharmaceuticals Acquires TWi Pharmaceutical
Packaging
* BD Launches Prefillable Syringe for Vaccines


Chemicals/Chemical API Manufacturing

Siegfried Breaks Ground on $104-M Drug-Substance Mfg Plant
Siegfried, a Zofingen, Switzerland-based CDMO, has broken ground on a CHF 100-million ($104- million) large-scale drug-substance production plant in Minden, Germany. The new facility, which is expected to start operations in 2024, will host up to 100 m3 additional reactor capacity.

Source: Siegfried


Lonza Completes HPAPI Mfg Expansion
Lonza has completed the expansion of its highly potent API (HPAPI) multipurpose manufacturing suite at its site in Visp, Switzerland, to development and manufacturing capacity for antibody drug conjugate payloads. The new HPAPI suite enables handling compounds with occupational exposure levels down to 1 ng/m3. Equipment on-site includes reactor sizes from 1 L to 50 L with a temperature range of -80°C to +150°C, isolation and drying equipment, and lyophilization and chromatography equipment for the manufacture of payload-linkers.

Source: Lonza


F.I.S. Creates Two Commercial Divisions, Appoints Executives to Lead
Fabbrica Italiana Sintetici (F.I.S.), a Montecchio Maggiore, Vicenza, Italy-based CDMO of active pharmaceutical ingredients and intermediates, has completed the reorganization of its commercial department through the creation of two new divisions: Generics and Custom. The company also announced that Gianluca Schiavoni, previously Sales Director at HRA Pharma, joins the company as Sales Director, Generics, and Luca Parlanti, PhD, who, previously was Head of Business Development, Custom Synthesis, at Siegfried, prior to joining F.I.S., takes on the role of Sales Director, Custom.

Source: Fabbrica Italiana Sintetici (F.I.S.)


Biologics Manufacturing

Lonza Name New Head of Cell & Gene Division
Lonza has named Daniel Palmacci, currently Senior Vice President and Global Head of Technical Operations and Executive Committee member at MorphoSys, a commercial-stage bio/pharmaceutical company, as President of Lonza’s Cell & Gene Division, effective November 1, 2022. He takes over the role from Jean-Christophe Hyvert, currently President, Biologics and Cell & Gene Divisions at Lonza, who will continue to serve as President of Lonza’s Biologics Division.

Palmacci has more than two decades of experience in the bio/pharmaceutical industry, including senior positions at Novartis and Bayer Healthcare and has international experience, having previously held roles in Switzerland, Germany, Italy, India, Brazil, France and the US.

Lonza’s expanded Executive Committee structure provides a dedicated President for each of Lonza’s four Divisions (Small Molecules, Biologics, Cell & Gene, and Capsules & Health Ingredients), and the appointment of Palmacci as President of Lonza’s Cell & Gene Division allows Hyvert to focus on his role of President of Lonza’s Biologics Division.

Source: Lonza


Formulation Development/Drug Product Manufacturing

WuXi STA Opens Sterile Lipid Nanoparticle Mfg Facility
WuXi STA, a CDMO and subsidiary of WuXi AppTec, has opened a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its site in Wuxi, China.  

The new facility integrates a multi-channel chip, a micro-mixer system, and a complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform to facilitate drug-loading, liposome particle-size control, and encapsulation efficiency. Additionally, the modular design enables the platform to serve manufacturing scales from 10-50 L per batch.

Source: WuXi STA


Pace Life Sciences Acquires Biopharma Global
Pace Life Sciences, a CDMO of drug products for clinical trial material supply, has acquired Biopharma Global, a Vienna, Virginia-based regulatory affairs firm. Biopharma Global specializes in regulatory support for orphan products to treat rare diseases and non-orphan products

Source: Pace Life Sciences


Bora Pharmaceuticals Acquires TWi Pharmaceutical
Bora Pharmaceuticals, a Tainan, Taiwan-based CDMO, has completed its acquisition of TWi Pharmaceutical, a Taipei, Taiwan-based pharmaceutical company specializing in development and commercialization of niche generic drugs. 

Acquiring TWi Pharmaceuticals adds two manufacturing facilities and will boost Bora’s service offerings in areas such as formulation development, sterile ophthalmic, and niche manufacturing technologies. 

TWi Pharmaceuticals USA operations will remain a separate entity.

Source: Bora Pharmaceuticals


Packaging

BD Launches Prefillable Syringe for Vaccines
Becton, Dickinson and Company (BD), a Franklin Lakes, New Jersey-based medical technology company, has launched a new glass prefillable syringe (PFS), BD Effivax Glass Prefillable Syringe,

for vaccines. The product launch is part of a previously announced larger $1.2 billion investment to expand and upgrade manufacturing capacity and technology for PFS.

Source: BD